Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

By Dr. Matthew Watson

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated randomized Phase II clinical trial evaluating its lead product candidate eftilagimod alpha (“efti” or “IMP321”) in hospitalized patients with COVID-19. The necessary approvals from the Czech Republic’s State Institute for Drug Control (SUKL- competent authority) and ethics committee have now been obtained, enabling the recruitment of patients to commence immediately. Initial interim results are expected to be reported from early 2021.

See the article here:
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

Related Post


categoriaGlobal News Feed commentoComments Off on Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients | dataOctober 24th, 2020

About...

This author published 5992 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2025